Astrotech Corp’s (NASDAQ: ASTC) subsidiary BreathTech Corporation has announced a joint agreement with Cleveland Clinic to develop a rapid COVID-19 breath test, causing a rally in Astrotech’s share price.
BreathTech’s press statement said the agreement will see the companies explore leveraging Astrotech’s BreathTest-1000 mass spectrometer to screen for the coronavirus with the goal being to develop a non-invasive device that uses breath samples to test for the virus.
If the joint venture is successful, it has the potential to provide a self-service solution that could be produced on a large scale.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
“Over the past months, both teams have evaluated and explored a framework to collaborate in the development of the BreathTech technology at Cleveland Clinic and believe that our mass-spec technology has potential to play an important role in providing a quick, non-invasive, easy-to-use screening device that can be utilized in hospitals, nursing homes, schools and airports in an effort to get all of our lives back to normal again,” stated Thomas B. Pickens III, CEO of BreathTech.
The news of the joint agreement has been received positively by investors as Astrotech’s share price jumped 194% post and premarket, to $4.98 after closing Tuesday at $1.69
PEOPLE WHO READ THIS ALSO VIEWED:
